Curcumin Efficacy in a Serum/Glucose Deprivation-Induced Neuronal PC12 Injury Model

Title:Curcumin Efficacy in a Serum/Glucose Deprivation-Induced Neuronal PC12 Injury Model

Volume: 14

Author(s): Tahereh Farkhondeh, Milad Ashrafizadeh, Mohsen Azimi-Nezhad, Fariborz Samini, Michael Aschner and Saeed Samarghandian*

Affiliation:

• Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur,Iran

Keywords: Apoptosis, curcumin, cytotoxicity, inflammation, oxidative stress, PC12 cell, serum/glucose deprivation.

Abstract:

Background: Glucose/serum deprivation (GSD), has been used for understanding molecular mechanisms of neuronal damage during ischemia. It has been suggested that curcumin may improve neurodegenerative diseases.

Aim: In this study, the protective effects of curcumin and its underlying mechanisms were investigated in PC12 cells upon GSD-induced stress.

Methods: PC12 cells were cultured in DMEM overnight and then incubated in GSD condition for either 6 or 12h. GSD-treated cells were pretreated with various concentrations of curcumin (10, 20, and 40 μM) for 5h. The cell viability, apoptosis, reactive oxygen species (ROS) level, oxidative stress, expression of apoptosis-related genes, and IL-6 were determined.

Results: Curcumin increased cell viability and caused an anti-apoptotic effect in PC12 cells exposed for 12h to GSD . Curcumin also increased antioxidant enzyme expression, suppressed lipid peroxidation, and decreased interleukin-6 secretion in PC12 cells subjected to GSD. In addition, pretreatment with curcumin down-regulated pro-apoptotic (Bax), and up-regulated antiapoptotic (Bcl2) mediators.

Conclusion: Curcumin mitigates many of the adverse effects of ischemia, and therefore, should be considered as an adjunct therapy in ischemic patients.

Cite this article as:

Farkhondeh Tahereh , Ashrafizadeh Milad , Azimi-Nezhad Mohsen , Samini Fariborz , Aschner Michael and Samarghandian Saeed *, Curcumin Efficacy in a Serum/Glucose Deprivation-Induced Neuronal PC12 Injury Model, Current Molecular Pharmacology 2021; 14 (6) : e301221191116 . https://dx.doi.org/10.2174/1874467214666210203211312